GSK3 beta Serine 389 Phosphorylation Modulates Cardiomyocyte Hypertrophy and Ischemic Injury

Autor: Vainio, Laura, Taponen, Saija, Kinnunen, Sini M., Halmetoja, Eveliina, Szabo, Zoltan, Alakoski, Tarja, Ulvila, Johanna, Junttila, Juhani, Lakkisto, Päivi, Magga, Johanna, Kerkelä, Risto

Prior studies show that glycogen synthase kinase 3 beta (GSK3 beta) contributes to cardiac ischemic injury and cardiac hypertrophy. GSK3 beta is constitutionally active and phosphorylation of GSK3 beta at serine 9 (S9) inactivates the kinase and prom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1593::2fb91c41fce164b343b25d6b8aaaf1cd
http://hdl.handle.net/10138/338942

Syväjohtamisen toteutuminen Suomen toimintaterapia-alalla

Autor: Taponen, Saija

Tarkoituksena tässä tutkimuksessa oli kuvata syväjohtajuuden ulottuvuuksien toteutumista toimintaterapia-alan johtajilla Suomessa. Työntekijät arvioivat lähijohtajiensa johtajuuskäyttäytymistä. Toimintaterapia-alan organisaatioihin kuuluvat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1222::ad702a11a305b33642b8be96b59fe355
http://urn.fi/URN:NBN:fi:jyu-201203191452

GSK3β Serine 389 Phosphorylation Modulates Cardiomyocyte Hypertrophy and Ischemic Injury.

Autor: Vainio L; Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu 90220, Finland.; Biocenter Oulu, University of Oulu, Oulu 90220, Finland., Taponen S; Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu 90220, Finland.; Biocenter Oulu, University of Oulu, Oulu 90220, Finland., Kinnunen SM; Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu 90220, Finland.; Drug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki 00014, Finland., Halmetoja E; Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu 90220, Finland.; Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu 90220, Finland., Szabo Z; Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu 90220, Finland., Alakoski T; Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu 90220, Finland.; Biocenter Oulu, University of Oulu, Oulu 90220, Finland., Ulvila J; Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu 90220, Finland., Junttila J; Biocenter Oulu, University of Oulu, Oulu 90220, Finland.; Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu 90220, Finland.; Research Unit of Internal Medicine, Division of Cardiology, Oulu University Hospital and University of Oulu, Oulu 90220, Finland., Lakkisto P; Unit of Cardiovascular Research, Minerva Institute for Medical Research, Helsinki 00014, Finland.; Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland., Magga J; Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu 90220, Finland.; Biocenter Oulu, University of Oulu, Oulu 90220, Finland., Kerkelä R; Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, Oulu 90220, Finland.; Biocenter Oulu, University of Oulu, Oulu 90220, Finland.; Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu 90220, Finland.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2021 Dec 18; Vol. 22 (24). Date of Electronic Publication: 2021 Dec 18.